Deutsche Bank AG Boosts Position in Harrow, Inc. (NASDAQ:HROW)

Deutsche Bank AG grew its position in Harrow, Inc. (NASDAQ:HROW - Free Report) by 100.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 108,064 shares of the company's stock after purchasing an additional 54,273 shares during the quarter. Deutsche Bank AG owned approximately 0.30% of Harrow worth $3,626,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also modified their holdings of the company. Tower Research Capital LLC TRC boosted its position in shares of Harrow by 769.5% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,652 shares of the company's stock worth $55,000 after acquiring an additional 1,462 shares during the last quarter. Aquatic Capital Management LLC bought a new position in Harrow during the fourth quarter valued at $78,000. AlphaQuest LLC lifted its position in Harrow by 452.8% during the fourth quarter. AlphaQuest LLC now owns 3,527 shares of the company's stock valued at $118,000 after purchasing an additional 2,889 shares during the last quarter. Federated Hermes Inc. bought a new position in Harrow during the fourth quarter valued at $214,000. Finally, Maridea Wealth Management LLC bought a new position in Harrow during the fourth quarter valued at $222,000. 72.76% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research firms have commented on HROW. B. Riley lowered their price objective on shares of Harrow from $69.00 to $65.00 and set a "buy" rating for the company in a research report on Tuesday, April 1st. HC Wainwright increased their price objective on shares of Harrow from $57.00 to $60.00 and gave the company a "buy" rating in a research report on Monday, May 12th.

Harrow Trading Up 0.6%

Shares of HROW traded up $0.16 during midday trading on Monday, hitting $25.90. The stock had a trading volume of 417,482 shares, compared to its average volume of 498,253. Harrow, Inc. has a 1 year low of $16.71 and a 1 year high of $59.23. The firm has a market cap of $950.14 million, a PE ratio of -27.55 and a beta of 0.41. The company has a debt-to-equity ratio of 3.23, a current ratio of 1.55 and a quick ratio of 1.44. The stock's 50 day moving average is $25.33 and its 200 day moving average is $30.92.

Harrow (NASDAQ:HROW - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of $0.02 by ($0.40). Harrow had a negative net margin of 19.75% and a negative return on equity of 45.57%. The firm had revenue of $47.83 million during the quarter, compared to analysts' expectations of $57.00 million. As a group, analysts forecast that Harrow, Inc. will post -0.53 EPS for the current fiscal year.

Harrow Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.